Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07276373 · ClinicalTrials.gov registry record · Phase 1
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
A Phase 1 study of Neoplasms, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT07276373: Recruiting Phase 1 study of Neoplasms, sponsored by Corcept Therapeutics.
NCT07276373 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 50 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07276373, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Nenocorilant 200 mg
- DRUG Nenocorilant 300 mg
- DRUG Nenocorilant 400 mg
Study Locations (3)
California
- Site 03 - Los Angeles
Texas
- Site 01 - San Antonio
Utah
- Site 02 - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT07276373 shows while recruiting
NCT07276373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT07276373 reports a single indexed study location in California, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT07276373 about?
NCT07276373 is a clinical study titled "Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies". This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
What is the current status of trial NCT07276373?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-01-16. Estimated completion is 2027-01.
What conditions does trial NCT07276373 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT07276373?
The interventions under investigation include: Nivolumab (DRUG), Nenocorilant 200 mg (DRUG), Nenocorilant 300 mg (DRUG), Nenocorilant 400 mg (DRUG).
Who is sponsoring clinical trial NCT07276373?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07276373 being conducted?
This trial has 3 study locations across California, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07276373's enrollment target sits among peer trials
50 105th of 158 higher than 52 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI